Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 1, 2004, Pages 217-223

  Abbate, Francesco ^a   Casini, Angela ^a   Owa, Takashi ^b   Scozzafava, Andrea ^a   Supuran, Claudiu T ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b EISAI CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMINO ACID; ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE INHIBITOR; INDISULAM; INDOLE DERIVATIVE; ISOENZYME; MEMBRANE ENZYME; METHAZOLAMIDE; SULFONAMIDE; TOPIRAMATE; WATER;

ARTICLE; CONCENTRATION RESPONSE; CONFORMATION; CRYSTAL STRUCTURE; CYTOSOL; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ENZYME LOCALIZATION; MOLECULAR INTERACTION; MOLECULE; X RAY ANALYSIS;

EID: 0348147633     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.09.062     Document Type: Article

References (39)

1. Scozzafava A., Owa T., Mastrolorenzo A., Supuran C.T. Curr. Med. Chem. 10:2003;925.
2. Supuran C.T., Scozzafava A., Casini A. Med. Res. Rev. 23:2003;146.
3. Casini A., Scozzafava A., Mastrolorenzo A., Supuran C.T. Curr. Cancer Drug Targets. 2:2002;55.
4. Owa T., Nagasu T. Exp. Opin. Ther. Pat. 10:2000;1725.
5. Supuran C.T., Scozzafava A. Exp. Opin. Ther. Pat. 12:2002;217.
6. Supuran C.T., Scozzafava A. Curr. Med. Chem. Imm., Endoc. Metab. Agents. 1:2001;61.
7. Supuran C.T., Scozzafava A. Exp. Opin. Ther. Pat. 10:2000;575.
8. Owa T., Yoshino H., Okauchi T., Yoshimatsu K., Ozawa Y., Sugi N.H., Nagasu T., Koyanagi N., Kitoh K. J. Med. Chem. 42:1999;3789.
9. Funahashi Y., Sugi N.H., Semba T., Yamamoto Y., Hamaoka S., Tsukahara-Tamai N., Ozawa Y., Tsuruoka A., Nara K., Takahashi K., Okabe T., Kamata J., Owa T., Ueda N., Haneda T., Yonaga M., Yoshimatsu K., Wakabayashi T. Cancer Res. 62:2002;6116.
10. Ozawa Y., Sugi N.H., Nagasu T., Owa T., Watanabe T., Koyanagi N., Yoshino H., Kitoh K., Yoshimatsu K. Eur. J. Cancer. 37:2001;2275.
11. Supuran C.T. Exp. Opin. Investig. Drugs. 12:2003;283.
12. van Kesteren C., Beijnen J.H., Schellens J.H. Anticancer Drugs. 13:2002;989.
13. Punt C.J., Fumoleau P., van de Walle B., Faber M.N., Ravic M., Campone M. Ann. Oncol. 12:2001;1289.
14. Raymond E., ten Bokkel Huinink W.W., Taieb J., Beijnen J.H., Faivre S., Wanders J., Ravic M., Fumoleau P., Armand J.P., Schellens J.H. J. Clin. Oncol. 20:2002;3508.
15. Fukuoka K., Usuda J., Iwamoto Y., Fukumoto H., Nakamura T., Yoneda T., Narita N., Saijo N., Nishio K. Invest. New Drugs. 19:2001;219.
16. Yokoi A., Kuromitsu J., Kawai T., Nagasu T., Sugi N.H., Yoshimatsu K., Yoshino H., Owa T. Mol. Cancer Ther. 1:2002;275.
17. Owa T., Yokoi A., Yamazaki K., Yoshimatsu K., Yamori T., Nagasu T. J. Med. Chem. 45:2002;4913.
18. Oda Y., Owa T., Sato T., Boucher B., Daniels S., Yamanaka H., Shinohara Y., Yokoi A., Kuromitsu J., Nagasu T. Anal. Chem. 75:2003;2159.
19. Pastorekova, S.; Pastorek, J. In Carbonic Anhydrase, Its Inhibitors and Activators; Supuran, C. T., Scozzafava, A., Conway, J., Eds.; Taylor & Francis: London and New York, in press.
20. Vullo D., Franchi M., Gallori E., Pastorek J., Scozzafava A., Pastorekova S., Supuran C.T. Bioorg. Med. Chem. Lett. 13:2003;1005.
21. Winum J.-Y., Vullo D., Casini A., Montero J.-L., Scozzafava A., Supuran C.T. J. Med. Chem. 46:2003;2197.
22. Ilies M.A., Vullo D., Pastorek J., Scozzafava A., Ilies M., Caproiu M.T., Pastorekova S., Supuran C.T. J. Med. Chem. 46:2003;2187.
23. Mincione F., Starnotti M., Menabuoni L., Scozzafava A., Casini A., Supuran C.T. Bioorg. Med. Chem. Lett. 11:2001;1787.
24. Scozzafava A., Menabuoni L., Mincione F., Briganti F., Mincione G., Supuran C.T. J. Med. Chem. 43:2000;4542.
25. Casini A., Antel J., Abbate F., Scozzafava A., David S., Waldeck H., Schäfer S., Supuran C.T. Bioorg. Med. Chem. Lett. 13:2003;841.
26. Parkkila S., Rajaniemi H., Parkkila A.-K., Kivelä J., Waheed A., Pastoreková S., Pastorek J., Sly W.S. Proc. Natl. Acad. Sci. U.S.A. 97:2000;2220.
27. Teicher B.A., Liu S.D., Liu J.T., Holden S.A., Herman T.S. Anticancer Res. 13:1993;1549.
28. 20.
29. 30.
30. 2 solutions in water at 20°C were used as substrate. Stock solutions of inhibitors were prepared at a concentration of 1-3 mM (in DMSO-water 1:1, v/v) and dilutions up to 0.1 nM done with the assay buffer mentioned above.
31. Sheldrick G.M. SHELX97. 1997;University of Göttingen, Göttingen, Germany.
32. Jones T.A., Cowan S.W., Kjeldgaard M. Acta Crystallogr. A47:1991;110.
33. free of 0.25). The final number of water molecules was 195.
34. Hakansson K., Carlsson M., Svensson L.A., Liljas A. J. Mol. Biol. 227:1992;1192.
35. Gruneberg S., Wendt B., Klebe G. Angew. Chem., Int. Ed. 40:2001;389.
36. Abbate F., Supuran C.T., Scozzafava A., Orioli P., Stubbs M., Klebe G. J. Med. Chem. 45:2002;3583.
37. Abbate F., Casini A., Scozzafava A., Supuran C.T. J. Enz. Inhib. Med. Chem. 18:2003;303.
38. Casini A., Abbate F., Scozzafava A., Supuran C.T. Bioorg. Med. Chem. Lett. 13:2003;2759.
39. The coordinates of the hCA II-E7070 adduct are available immediately from claudiu.supuran@unifi.it.